作者
Peng Jiang,Chan Wang,Mingming Zhang,Ye Tian,Weifeng Zhao,Junyi Xin,Yijiang Huang,Zhibin Zhao,Wenjuan Sun,Jie Long,Ruqi Tang,Fang Qiu,Xingjuan Shi,Yi Zhao,Li Zhu,Na Dai,Lei Liu,Xudong Wang,Jianhui Nie,Ben‐Yuan Jiang,Youlin Shao,Yueqiu Gao,Jianjiang Yu,Zhigang Hu,Zhidong Zang,Yuhua Gong,Yaping Dai,Lan Wang,Ningling Ding,Peng Xu,Sufang Chen,Lu Wang,Jiefeng Xu,Luyao Zhang,Jun‐Yan Hong,Ruonan Qian,H.-Y. Li,Xuan Jiang,Congwei Chen,Wenyan Tian,Jian Wu,Yahui Jiang,Chongxu Han,Kui Zhang,Hong Qian,Li Li,Hong Fan,Liming Chen,Jianqiong Zhang,Zhen Sun,Xia Han,Zhenhua Dai,Erguang Li,M. Eric Gershwin,Zhe‐Xiong Lian,Xiong Ma,Michael F. Seldin,Weichang Chen,Meilin Wang,Xiangdong Liu
摘要
Osteoarthritis (OA) is one of the most common degenerative joint diseases worldwide, causing pain, disability, and decreased quality of life. The balance between regeneration and inflammation-induced degradation results in multiple etiologies and complex pathogenesis of OA. Currently, there is a lack of effective therapeutic strategies for OA treatment. With the development of CRISPR-based genome, epigenome, and RNA editing tools, OA treatment has been improved by targeting genetic risk factors, activating chondrogenic elements, and modulating inflammatory regulators. Supported by cell therapy and in vivo delivery vectors, genome, epigenome, and RNA editing tools may provide a promising approach for personalized OA therapy. This review summarizes CRISPR-based genome, epigenome, and RNA editing tools that can be applied to the treatment of OA and provides new insights into the development of CRISPR-based therapeutics for OA treatment. Moreover, in-depth evaluations of the efficacy and safety of these tools in human OA treatment are needed.